Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143412 |
| CAS No | NA |
| Mol.F. | C24H24F2N6O3 |
| Mol.Wt. | 482.19 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143413 |
| CAS No | NA |
| Mol.F. | C29H32F2N6O5 |
| Mol.Wt. | 582.61 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143414 |
| CAS No | NA |
| Mol.F. | C23H25BF2N2O4 |
| Mol.Wt. | 442.27 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143415 |
| CAS No | NA |
| Mol.F. | C26H24F2N6O4 |
| Mol.Wt. | 522.51 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143416 |
| CAS No | NA |
| Mol.F. | C21H22N2O5S |
| Mol.Wt. | 414.48 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143417 |
| CAS No | NA |
| Mol.F. | C12H14N2O4S |
| Mol.Wt. | 282.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143418 |
| CAS No | NA |
| Mol.F. | C14H16N2O5S |
| Mol.Wt. | 324.35 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143419 |
| CAS No | NA |
| Mol.F. | C24H27N3O7S2 |
| Mol.Wt. | 533.61 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143420 |
| CAS No | NA |
| Mol.F. | C19H20N2O4S |
| Mol.Wt. | 372.44 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143421 |
| CAS No | NA |
| Mol.F. | C38H39N3O7S2 |
| Mol.Wt. | 713.86 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143422 |
| CAS No | NA |
| Mol.F. | C19H18N2O4 |
| Mol.Wt. | 338.36 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143423 |
| CAS No | NA |
| Mol.F. | C13H16N2O4S |
| Mol.Wt. | 296.34 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143424 |
| CAS No | NA |
| Mol.F. | C15H18N2O5S |
| Mol.Wt. | 338.38 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143425 |
| CAS No | NA |
| Mol.F. | C21H22N2O6S |
| Mol.Wt. | 430.48 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143426 |
| CAS No | NA |
| Mol.F. | C18H22N2O4 |
| Mol.Wt. | 330.38 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143427 |
| CAS No | NA |
| Mol.F. | C18H22N2O3 |
| Mol.Wt. | 314.39 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |